Tumor immune killing depends not only on whether immune cells are present, but also on the balance between inhibitory and activating signals. NKG2A restricts NK cell and CD8⁺ T cell function through HLA-E, whereas NKG2D recognizes tumor stress ligands and enhances immune killing. Together, these ...